natgillin/translations-raw huggingface dataset:
Of the total number of subjects in clinical studies of Velphoro, 29.7 % were aged 65 and over, while 8.7% were aged 75 and over.
Od skupnega števila bolnikov v kliničnih študijah zdravila Velphoro je bilo 29,7 % starih 65 let in več, medtem ko je bilo 8,7 % starih 75 let in več.
Of the total number of women in Phase 3 clinical trials who received CE/bazedoxifene 20 mg, 2.4% (n=77) were aged ≥65 years.
Od skupnega števila žensk v kliničnih preskušanjih 3. faze, ki so prejemale CE/bazedoksifen, jih je bilo 2,4 % (n = 77) starih ≥ 65 let.
Of them, all reported vascular elbow lesions, but also neurologic symptoms (1 case), bone and muscle pain (2 cases), and skin striae (2 cases).
Pri vseh se je pojavila vaskularna lezija komolca, poleg tega pa še nevrološki simptomi (1 primer), bolčine v kosteh in mišicah (2 primera) in kožne strije (2 primera).
Of these 17 patients, there were 5 patients who discontinued treatment.
Od teh 17 bolnikov je bilo 5 bolnikov, ki so prekinili zdravljenje.
Of these 25 patients, 20 had a decrease in inhibitor titres to < 0.6 BU/mL, of whom initially 11 of 15 had high titres (≥ 5 BU/mL) and 9 of 10 had low titres.
Od teh 25 bolnikov jih je 20 imelo titre inhibitorja znižane na < 0,6 B.e./ml; od teh jih je na začetku 11 od 15 imelo visoke titre (≥ 5 B.e./ml), 9 od 10 pa nizke titre.
Of these 34 patients, none experienced severe (NCI-CTCAE Grade 4) infusion or hypersensitivity reactions (anaphylaxis) that were clearly related to ATA.
Pri nobenem od teh 34 bolnikov se ni pojavila huda infuzijska reakcija stopnje 4 po merilih NCI-CTCAE ali huda preobčutljivostna reakcija (anafilaksija) stopnje 4 po merilih NCI-CTCAE, ki bi bila jasno povezana z ATA.
Of these 41 patients, 29 presented with disorders in primary bile acid synthesis including Sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX) deficiency (n=4).
Od teh 41 bolnikov jih je imelo 29 motnje v sintezi primarnih žolčnih kislin, vključno s pomanjkanjem sterol 27-hidroksilaze (ki se kaže kot cerebrotendinozna ksantomatoza, CTX) (n = 4).
Of these 41 patients, 29 presented with disorders in primary bile acid synthesis including Sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX) deficiency (n=4).
Od teh 41 bolnikov jih je imelo 29 motnje v sintezi primarnih žolčnih kislin, vključno s: pomanjkanje sterol 27-hidroksilaze (ki se kaže kot cerebrotendinozna ksantomatoza, CTX) (n = 4).
Of these 51 patients, 70.6% achieved clinical response and 39.2% percent achieved clinical remission 16 weeks after receiving the first subcutaneous dose of ustekinumab.
Če bolnik dobi resno okužbo, ga morate pozorno spremljati in mu zdravila STELARA ne smete več dajati, dokler okužba ne mine.
Of these 6,684 were treated with 150 mg or 220 mg daily of Pradaxa.
Od teh so jih 6684 zdravili s 150 ali 220 mg zdravila Pradaxa na dan.
Of these 692 patients, 613 (300 atazanavir/cobicistat and 313 atazanavir/ritonavir) and 496 (250 atazanavir/cobicistat and
Med temi 692 bolniki se jih je 613 (300 atazanavir/kobicistat in
Of these 7 patients,3 had eye, 1 had sinus, and 3 had disseminated infection.
Od teh 7 bolnikov so 3 imeli okužbo oči, 1 okužbo sinusov in 3 diseminirano okužbo.
Of these 79 patients, 66 (83.5%) were laBCC patients (37 [46.8%] with aggressive histology and 29 [36.7%] with non-aggressive histology) and 13 (16.5%) were mBCC patients.
Med temi 79 bolniki jih je 66 (83,5 %) imelo lokalno napredovali bazalnocelični karcinom (od tega 37 [46,8 %] z agresivnim histološkim tipom in 29 [36,7 %] z neagresivnim histološkim tipom), 13 (16,5 %) pa jih je imelo metastatski bazalnocelični karcinom.
Of these discontinuations, 7 in the Stribild group and 1 in the ATV/r+FTC/TDF group occurred during the first 48 weeks.
Med temi prekinitvami je do 7 v skupini z zdravilom Stribild in 1 v skupini z ATV/r+FTC/TDF prišlo v prvih 48 tednih.
Of these events, 40.5% in the Stivarga arm and 66.7% in the placebo arm have been reported as not recovered / not resolved.
Za 40,5 % teh dogodkov v skupini bolnikov, zdravljenih z zdravilom Stivarga, in 66,7 % v skupini bolnikov, ki so prejemali placebo, so poročali, da bolniki niso okrevali/učinki niso izzveneli.
Of these four, two subjects had a unique R263K integrase substitution, with a maximum FC of 1.93, one subject had a polymorphic V151V/I integrase substitution, with maximum FC of 0.92, and one subject had pre-existing integrase mutations and is assumed to have been integrase experienced or infected with integrase resistant virus by transmission.
Od teh štirih sta dve osebi imeli edinstveno substitucijo integraze R263K, z maksimalno vrednostjo FC 1,93, ena oseba je imela polimorfno substitucijo integraze V151V/I z maksimalno vrednostjo FC 0,92, ena oseba pa je imela že obstoječe mutacije integraze in se predpostavlja, da je predhodno že dobivala zdravila iz skupine zaviralcev integraze ali je bila preko prenosa okužena z virusom, odpornim na integrazo.
Of these patients, 100% (7 out of 7) mobilised ≥ 2 x106/kg CD34+ cells and had successful engraftment.
Od teh bolnikov jih je 100 % (7 od 7) mobiliziralo ≥ 2 x106/kg celic CD34+ in so prestali uspešno presaditev.
Of these patients, 211 patients were treated with trametinib for BRAF V600 mutant melanoma in a randomised open label phase III study (see section 5.1).
Od teh bolnikov jih je bilo 211 zdravljenih s trametinibom zaradi melanoma z mutacijo BRAF V600 v randomizirani odprti študiji III. faze (glejte poglavje 5.1).
Of these patients, 248 are from the Phase 3 study in previously untreated CML patients, 570 and 52 are from two Phase 1/2 studies in previously treated Ph+ leukaemias.
Od teh bolnikov jih je 248 iz klinične študije 3. faze pri predhodno nezdravljenih bolnikih s KML, 570 in 52 pa jih je iz dveh kliničnih študij 1./2. faze pri predhodno zdravljenih bolnikih s Ph+ levkemijami.
Of these patients, 55 % (34 out of 62) mobilised ≥ 2 x106/kg CD34+ cells and had successful engraftment.
Od teh bolnikov jih je 55 % (34 od 62) mobiliziralo ≥ 2 x 106/kg celic CD34+ in so prestali uspešno presaditev.
Of these patients, 55/57 (96%) had histological improvement as previously defined (see above), and 50/57 (88%) had a ≥ 1- point decrease in Ishak fibrosis score.
Izboljšanje histološke slike po prejšnji definiciji (glejte zgoraj) je bilo ugotovljeno pri 55/57 bolnikov (96%), zmanjšanje indeksa fibroze po Ishak-u za ≥ 1 točko pa pri 50/57 bolnikov (88%).
Of these patients, 55/57 (96%) had histological improvement as previously defined (see above), and 50/57 (88%) had a ≥ 1- point decrease in Ishak fibrosis score.
Izboljšanje histološke slike po prejšnji definiciji (glejte zgoraj) je bilo ugotovljeno pri 55/57 bolnikov (96%), zmanjšanje indeksa fibroze po Ishak-u za ≥ 1-točko pa pri 50/57 bolnikov (88%).
Of these patients, 84% experienced adverse events and 15% experienced serious adverse events.
Neželeni učinki so se pojavili pri 84 % od teh bolnikov, 15 % bolnikov je imelo resne neželene učinke.
Of these patients, 892 patients received linaclotide at the recommended dose of 290 micrograms per day.
892 od teh bolnikov je prejemalo linaklotid v priporočenemu odmerku 290 mikrogramov na dan.
Of these subjects, 3618 subjects received the mock-up vaccine Foclivia (A/H5N1) (see section 5.1)
Med njimi je 3.618 oseb prejelo demonstracijsko cepivo Foclivia (A/H5N1) (glejte poglavje 5.1).
Of these subjects, 3618 subjects received the mock-up vaccine Foclivia (A/H5N1) (see section 5.1).
Med njimi je 3.618 oseb prejelo demonstracijsko cepivo Foclivia (A/H5N1) (glejte poglavje 5.1).
Of these virologic failures 5/15 (rilpivirine) and 5/14 (efavirenz) were in patients with a baseline viral load of
Med temi virološkimi neuspehi je bilo 5/15 (rilpivirin) in 5/14 (efavirenz) bolnikov z začetno virusno obremenitvijo
Of these, 1,139 were ≥ 65 years of which 115 were ≥ 75 years.
V teh študijah je bilo 1139 bolnikov starih ≥ 65 let, od teh pa je bilo 115 bolnikov starih ≥ 75 let.
Of these, 187 patients aged 6 years and above were exposed to Colobreathe one capsule twice daily in a 24-week, phase 3 comparative study.
Med njimi je bilo 187 bolnikov, starih 6 let ali več, izpostavljenih zdravilu Colobreathe ena kapsula dvakrat na dan v 24-tedenski primerjalni študiji faze 3.
Of these, 2,190 psoriasis patients were exposed to Taltz for at least one year, representing 3,531 patient years of exposure.
Od teh bolnikov je bilo 2190 bolnikov s psoriazo izpostavljenih zdravilu Taltz vsaj eno leto, kar predstavlja 3531 bolnik-let izpostavljenosti.
Of these, 28 patients (93%) achieved a 20% or greater reduction of parenteral support.
Od teh jih je 28 (93 %) doseglo 20- ali več-odstotno znižanje parenteralne prehranske podpore.
Of these, 3 patients achieved complete remission (27%), 1 patient had partial remission (9%), 1 patient had haematologic improvement (9%) and 2 patients had therapeutic efficacy (18%).
Od teh so 3 bolniki dosegli popolno remisijo (27 %), 1 bolnik je dosegel delno remisijo (9 %), 1 bolnik je dosegel hematološko izboljšanje (9 %) in 2 bolnika sta dosegla terapevtsko učinkovitost (18 %).
Of these, 3,671 patients were exposed to Cosentyx for at least one year, representing 6,450 patient years of exposure.
Med njimi je bilo 3.671 bolnikov izpostavljenih zdravilu Cosentyx najmanj eno leto, kar predstavlja 6.450 bolnikov-let izpostavljenosti zdravilu.
Of these, 311 patients had been treated with tadalafil for at least 6 months and 293 for 1 year (median exposure 365 days; range 2 days to 415 days).
Od tega se je 311 bolnikov s tadalfilom zdravilo najmanj 6 mesecev, 293 pa 1 leto (povprečna izpostavljenost je bila 365 dni, obseg od 2 dni do 415 dni).
Of these, 37 had invasive candidiasis, 10 had invasive aspergillosis, and 1 patient had esophageal candidiasis.
Od teh jih je 37 imelo invazivno kandidiazo, 10 invazivno aspergilozo in 1 bolnik ezofagealno kandidiazo.
Of these, 4 of the 5 AP patients had notable treatment duration with a range from 46 to 114 weeks with responses including CMR (1 patient), CCyR
Pri 4 od 5 bolnikov v pospešeni fazi je trajanje zdravljenja znašalo od 46 do 114 tednov, z odzivi, ki so vključevali CMR
Of these, 427 completed 2 years of open- label follow-up and thus had a total exposure to Cimzia of 148 weeks overall.
Od teh jih je 427 zaključilo 2-letno odprto sledilno študijo in bilo celotno izpostavljeno zdravilu Cimzia 148 tednov.
Of these, 45 went on to a fourth, long-term study looking at the effectiveness of Mimpara over a total of almost six years.
Od teh jih je 45 sodelovalo tudi v četrti, dolgoročni študiji, ki je proučevala učinkovitost zdravila Mimpara v trajanju skoraj šest let.
Of these, 45 went on to a fourth, long-term study looking at the effectiveness of Parareg over a total of almost six years.
Od teh jih je 45 nadaljevalo v četrti, dolgoročni študiji, ki je preučevala učinkovitost zdravila Parareg v trajanju skoraj šest let.
Of these, 5.1% were mild and 1.0% were moderate and 0.1% were classified as severe.
Od tega je bilo 5,1 % opredeljenih kot blagi, 1,0 % kot zmerni in 0,1 % kot hudi.
Of these, 900 patients patients have been treated for one year or longer.
Med njimi je 900 bolnikov prejemalo zdravilo eno leto ali dlje.
Of these, a total of 77 were randomised to receive OZURDEX, 76 to dexamethasone 350 µg and 76 to sham.
Od teh so jih skupno 77 naključno izbrali za zdravljenje z zdravilom OZURDEX, 76 z deksametazonom 350 µg in 76 s placebom.
Of those cases 20 reported paraesthesia within one to three days of vaccination, including 17 cases where paraesthesia was the primary symptom.
Med njimi je bila v 20 primerih parestezija poročana v roku enega do treh dni po cepljenju, vključno s 17 primeri, kjer je bila parestezija primarni simptom.
Of those forty-three (43) patients, two(2) siblings withdrew at the end of the first crossover period, due to a prior planned surgery in one (1) of them; forty-one (41) patients completed the protocol.
Od teh triinštiridesetih (43) bolnikov sta dva (2) posameznika, brat in sestra, na koncu prvega obdobja navzkrižnega preskušanja prekinila zdravljenje zaradi predhodno načrtovane operacije enega (1) od njiju; študijo je dokončalo enainštirideset (41) bolnikov.
Of those in clinical response at Week 4, 48% had been previously exposed to other TNF-antagonists.
Od teh s kliničnim odzivom v 4.tednu jih je bilo 48 % prej izpostavljenih drugim TNF-antagonistom.
Of those in clinical response at Week 4, 48% had been previously exposed to other TNF-antagonists.
Od tistih, ki so imeli 4. teden klinični odziv, jih je 48 % predhodno dobilo antagoniste TNF.
Of those patients who had a response at Week 8, 47% were in response, 29% were in remission, 41% had mucosal healing, and 20% were in steroid-free remission for ≥ 90 days at Week 52.
Od bolnikov, ki so bili odzivni v 8.tednu, jih je bilo v 52. tednu 47 % odzivnih, 29 % v remisiji, 41 % je imelo celjenje sluznice in 20 % jih je bilo v remisiji brez steroidov za ≥ 90 dni.
Of those patients who had a response at Week 8, 47% were in response, 29% were in remission, 41% had mucosal healing, and 20% were in steroid-free remission for ≥ 90 days at Week 52.
Od bolnikov, ki so bili odzivni v 8.tednu, jih je bilo v 52.tednu 47 % odzivnih, 29 % v remisiji, 41 % je imelo celjenje sluznice in 20 % jih je bilo v remisiji brez steroidov za ≥ 90 dni.
Of those patients who had infusion related reactions, those dosed with vedolizumab had more infusion related reactions with in the first two hours as compared to placebo patients with infusion related reactions.
Pri bolnikih, pri katerih so se pojavile reakcije, povezane z infundiranjem, se je več tovrstnih reakcij v prvih dveh urah po infundiranju pojavilo pri bolnikih, ki so prejemali vedolizumab, v primerjavi z bolniki, ki so prejemali placebo.
Of those who were rechallenged, 95 (97%) did not have a subsequent event or did not discontinue bosutinib due to a subsequent event of diarrhoea.
Od teh, ki so začeli s ponovnim jemanjem zdravila, jih 95 (97 %) ni doživelo ponovnega pojava diareje ali ni prekinilo z jemanjem bosutiniba zaradi ponovnega pojava diareje.
of trazodone and ritonavir.
uporabljen v študiji)
of UGT1A1 and CYP3A
UGT1A1 in CYP3A)
of voriconazole.
vorikonazola.
Ofatumumab does not have a clinically relevant effect on the pharmacokinetics of chlorambucil or its active metabolite, phenylacetic acid mustard.
Ofatumumab ne vpliva klinično pomembno na farmakokinetiko klorambucila in njegovega aktivnega presnovka, fenilacetoiperita.
Ofatumumab has a small volume of distribution, with mean Vss values ranging from 1.7 to 8.1 l across studies, dose levels, and infusion number.
Ofatumumab ima majhen volumen porazdelitve; povprečna vrednost Vss v različnih študijah, z različnimi odmerki in različnim številom infuzij sega od 1,7 do 8,1 l.
Ofatumumab has also been shown to induce cell lysis in both high and low CD20 expressing cells and in rituximab- resistant cells.
Prav tako je dokazano, da ofatumumab povzroči lizo celic z veliko in majhno izraženostjo CD20 in v celicah, odpornih proti rituksimabu.
Ofatumumab is administered by intravenous infusion; therefore, absorption is not applicable.
Ofatumumab se uporablja v intravenski infuziji, zato podatki o absorpciji niso smiselno potrebni.
Ofev 100 mg capsules are peach-coloured, opaque, oblong soft-gelatin capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “100”.
Zdravilo Ofev 100 mg mehke kapsule so neprozorne podolgovate mehke želatinske kapsule v barvi breskve, ki imajo na eni strani v črni barvi natisnjeno oznako podjetja Boehringer Ingelheim in številko “100”.
Ofev 100 mg soft capsules are peach-coloured, opaque, oblong soft-gelatin capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and “100”.
Zdravilo Ofev 100 mg mehke kapsule so neprozorne in podolgovate želatinske kapsule v barvi breskve, ki imajo na eni strani črno natisnjeno oznako podjetja Boehringer Ingelheim in številko “100”.
Ofev 100 mg soft capsules Ofev 150 mg soft capsules
Ofev 100 mg mehke kapsule Ofev 150 mg mehke kapsule
Ofev 100 mg soft capsules/ Ofev 150 mg soft capsules are available in the following pack-sizes:
Zdravilo Ofev 100 mg mehke kapsule/Ofev 150 mg mehke kapsule je na voljo v naslednjih velikostih pakiranj:
Ofev 150 mg capsules are brown-coloured, opaque, oblong soft-gelatin capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “150”.
Zdravilo Ofev 150 mg mehke kapsule so rjave podolgovate mehke želatinske kapsule, ki imajo na eni strani v črni barvi natisnjeno oznako podjetja Boehringer Ingelheim in številko “150”.
Ofev 150 mg soft capsules are brown-coloured, opaque, oblong soft-gelatin capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and “150”.
Zdravilo Ofev 150 mg mehke kapsule so neprozorne in podolgovate želatinske kapsule rjave barve, ki imajo na eni strani črno natisnjeno oznako podjetja Boehringer Ingelheim in številko “150”.
Ofev 150 mg twice daily
Zdravilo Ofev 150 mg dvakrat na dan
Ofev contains soya lecithin
Zdravilo Ofev vsebuje sojin lecitin.
Ofev contains the active substance nintedanib and it is used for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Zdravilo Ofev vsebuje zdravilno učinkovino nintedanib in se uporablja za zdravljenje idiopatske pljučne fibroze (IPF).
Ofev has minor influence on the ability to drive and use machines.
Zdravilo Ofev ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Zdravilo Ofev je indicirano za zdravljenje odraslih bolnikov z idiopatsko pljučno fibrozo (IPF).
Ofev may have minor influence on your ability to drive and use machines.
Zdravilo Ofev ima lahko blag vpliv na sposobnost vožnje in upravljanja s stroji.
Ofev should not be taken by children and adolescents under 18 years of age.
Otroci in mladostniki, stari manj kot 18 let, ne smejo jemati zdravila Ofev.
Ofev treatment may be resumed at a reduced dose (100 mg twice daily) or at the full dose (150 mg twice daily).
Zdravljenje lahko nadaljujete z zmanjšanim odmerkom (100 mg dvakrat na dan) ali s polnim odmerkom (150 mg dvakrat na dan).
OFF time (hrs) (c)
Obdobje težav z gibanjem (»izklop«) (ure) (c)
OFF TOBI Podhaler
brez jemanja zdravila TOBI Podhaler
OFF Vantobra
Brez uporabe zdravila Vantobra
off with the gauze pad and apply an adhesive
obrišite z gazo in nanj položite lepljiv povoj
OFF-time reduction
Skrajšanje časa izklopa
Off-white or pink suspension for injection
Belkasta ali rožnata suspenzija za injiciranje
Off-white or pink suspension for injection
Belkasta do rožnata suspenzija za injiciranje
Off-white round, film-coated tablet embossed 100 on one side.
Sivobela, okrogla, filmsko obložena tableta z vtisom 100 na eni strani.
Off-white to light yellow soluble tablet with “177” imprinted on one face.
Belkaste do svetlo rumene tablete za peroralno raztopino z napisom “177” na eni strani.
Off-white, capsule-shaped, film-coated tablet with triple scoring on both sides.
Sivobela, filmsko obložena tableta v obliki kapsule (tableta) s tremi zarezami na obeh straneh.
Off-white, round, flat tablets with bevelled edges and imprints (NVR on one face and J 125 on the other).
Sivo bele, okrogle, ploščate tablete z zaobljenimi robovi in vtisnjenima oznakama (NVR na eni in J 125 na drugi strani).
Off-white, round, flat tablets with bevelled edges and imprints (NVR on one face and J 250 on the other).
Sivo bele, okrogle, ploščate tablete z zaobljenimi robovi in vtisnjenima oznakama (NVR na eni in J 250 na drugi strani).
Off-white, round, flat tablets with bevelled edges and imprints (NVR on one face and J 500 on the other).
Sivo bele, okrogle, ploščate tablete z zaobljenimi robovi in vtisnjenima oznakama (NVR na eni in J 500 na drugi strani).
Offer to birds immediately.
Takoj dajte piščancem.
Official and local antimicrobial policies should be taken into account when the product is used.
Upoštevati je potrebno uradno in lokalno usmeritev glede uporabe antimikrobnih zdravil za uporabo v veterinarski medicini.
Official batch release
Uradno sproščanje serije
Official batch release: in accordance with Article 114 of Directive 2001/83/EC, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.
Uradna sprostitev serije: v skladu s 114. členom Direktive 2001/83/ES, serijo uradno sprosti državni laboratorij ali laboratorij, določen v ta namen.
Official control authority batch release is required for this product.
Za to zdravilo je potreben postopek uradne kontrole in sproščanja (OCABR postopek)
official guidance on the appropriate treatment of tuberculosis in HIV infected patients.
virusom HIV, je treba upoštevati uradne smernice za ustrezno zdravljenje tuberkuloze.
Official recommendations for the immunisation against diphtheria, tetanus and Haemophilus influenzae type b should also be followed.
Vedno je treba upoštevati uradna priporočila za imunizacijo proti davici, tetanusu in Haemophilus influenzae tipa b.
Official, national and regional antimicrobial policies should be taken into account when the product is used.
Pri uporabi zdravila je treba poštevati uradna, nacionalna in področna pravila glede uporabe protimikrobnih zdravil.
Official, national and regional antimicrobial policies should be taken into account when the product is used.
Pri uporabi zdravila je treba poštevati uradna, nacionalna in področna pravila uporabe protimikrobnih zdravil.
Official, national and regional antimicrobial policies should be taken into account when the product is used.
Uradno, državno in lokalno antimikrobno politiko je treba upoštevati vedno, kadar uporabljate zdravilo za uporabo v veterinarski medicini.
Offset of action
Konec delovanja
Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (≥20 micrograms/kg/day) and slightly reduced survival rate (100 micrograms/kg/day).
Pri potomcih podgan, ki so jim dali pegfilgrastim v času poroda ali dojenja, so opazili zamudo v zunanji diferenciaciji in rasti (≥20 mikrogramov/kg/dan) in nekoliko zamnjšano stopnjo preživetja (100 mikrogramov/kg/dan).
Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (≥20 µg/kg/day) and slightly reduced survival rate (100 µg/kg/day).
Pri potomcih podgan, ki so prejemale filgrastim v obporodnem obdobju in med dojenjem, so zabeležili zaostanek pri zunanji diferenciaciji in zastoj v rasti (≥ 20 µg/kg/dan) ter nekoliko zmanjšano stopnjo preživetja (100 µg/kg/dan).
oft faeces to mild diarrhoea, in cats only fatigue during the treatment, in cats only
mehko blato do blaga diareja, samo pri mačkah, utrujenost med zdravljenjem, samo pri mačkah.
oftening of the bones (with bone pain and sometimes resulting in fractures) back pain caused by kidney problems
mehčanje kosti (z bolečinami v kosteh, včasih tudi zlom) bolečine v križu zaradi ledvične okvare
oftening of the bones (with bone pain and sometimes resulting in fractures). back pain caused by kidney problems.
mehčanje kosti (z bolečinami v kosteh, včasih tudi zlom), bolečine v križu zaradi ledvične okvare.
Oher medicines and Insulin Human Winthrop Rapid
Druga zdravila in Insulin Human Winthrop Rapid
OHSS is a medical event distinct from uncomplicated ovarian enlargement.
OHSS je medicinski zaplet, ki se razlikuje od nezapletenega povečanja jajčnikov.
OHSS is a serious medical problem that can happen when the ovaries are overly stimulated.
To je resna zdravstvena motnja, ki se lahko pojavi pri prekomerni stimulaciji jajčnikov.
OHSS may become a serious medical event characterised by large ovarian cysts which are prone to rupture, weight gain, dyspnoea, oliguria or the presence of ascites within a clinical picture of circulatory dysfunction.
OHSS se lahko razvije v resen zaplet, za katerega so značilne velike ciste na jajčnikih, nagnjene k rupturi, povečanje telesne mase, dispneja, oligurija ali pojav ascitesa v klinični sliki disfunkcije obtočil.